4.7 Article

L-Glutamine for sickle cell anemia: more questions than answers

Journal

BLOOD
Volume 132, Issue 7, Pages 689-693

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-03-834440

Keywords

-

Categories

Funding

  1. Amgen, Inc
  2. Global Blood Therapeutics, Inc.

Ask authors/readers for more resources

In 2017, the Food and Drug Administration approved 2 medications for sickle cell anemia (SCA): hydroxyurea for children and L-glutamine for children and adults. The approval of hydroxyurea was long overdue, but the approval of L-glutamine was a surprise to many. Any effective new treatment for SCA is a welcome advance, but there are few published studies of L-glutamine as a specific treatment for SCA. Accordingly, there are many unanswered questions about its efficacy, safety, and role in current therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available